$563 Million is the total value of Rhenman & Partners Asset Management AB's 97 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Buy | Alexion Pharmaceuticals Inc | $26,047,000 | +54.6% | 223,082 | +84.4% | 4.62% | +38.3% |
| GILD | Buy | Gilead Sciences Inc | $20,021,000 | +21.1% | 240,000 | +33.3% | 3.56% | +8.3% |
| CELG | Buy | Celgene Corp | $19,627,000 | +63.4% | 199,000 | +65.8% | 3.48% | +46.2% |
| BIIB | Buy | Biogen Inc | $19,346,000 | +95.6% | 80,000 | +110.5% | 3.44% | +74.9% |
| LLY | Buy | Eli Lilly & Co | $18,506,000 | +31.8% | 235,000 | +20.5% | 3.29% | +17.9% |
| REGN | Buy | Regeneron Pharmaceuticals Inc | $17,287,000 | +299.7% | 49,500 | +312.5% | 3.07% | +257.4% |
| CI | Buy | Cigna Corp | $12,671,000 | +33.8% | 99,000 | +43.5% | 2.25% | +19.7% |
| AGN | Buy | Allergan Plc | $12,017,000 | +6.8% | 52,000 | +23.8% | 2.13% | -4.5% |
| UNH | Buy | United Health Group Inc | $12,002,000 | +55.2% | 85,000 | +41.7% | 2.13% | +38.8% |
| CVS | Buy | CVS Health Corp | $11,489,000 | +5.5% | 120,000 | +14.3% | 2.04% | -5.6% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $10,821,000 | +37.9% | 195,000 | +56.0% | 1.92% | +23.4% |
| ENDP | Buy | Endo International Plc | $9,903,000 | +35.3% | 635,200 | +144.3% | 1.76% | +21.1% |
| JAZZ | Buy | Jazz Pharmaceuticals Plc | $9,892,000 | +152.5% | 70,000 | +133.3% | 1.76% | +125.8% |
| AMGN | Buy | Amgen Inc | $9,357,000 | +38.7% | 61,500 | +36.7% | 1.66% | +24.1% |
| ESRX | Buy | Express Scripts Hg Co | $8,793,000 | +20.8% | 116,000 | +9.4% | 1.56% | +8.0% |
| CPHD | Buy | Cepheid Inc | $7,995,000 | +59.8% | 260,000 | +73.3% | 1.42% | +43.0% |
| EW | Buy | Edwards Lifesciences Corp | $6,981,000 | +43.9% | 70,000 | +27.3% | 1.24% | +28.8% |
| EXEL | Buy | Exelixis Inc | $6,248,000 | +140.3% | 800,000 | +23.1% | 1.11% | +114.9% |
| HOLX | Buy | Hologic Inc | $6,228,000 | +200.9% | 180,000 | +200.0% | 1.11% | +169.1% |
| ABC | Buy | AmerisourceBergen Corp | $6,187,000 | +13.5% | 78,000 | +23.8% | 1.10% | +1.6% |
| HZNP | Buy | Horizon Pharma Plc | $6,094,000 | +83.9% | 370,000 | +85.0% | 1.08% | +64.4% |
| MD | New | Mednax Inc | $5,794,000 | – | 80,000 | +100.0% | 1.03% | – |
| SUPN | Buy | Supernus Pharmaceuticals Inc | $5,704,000 | +38.5% | 280,000 | +3.7% | 1.01% | +24.0% |
| HUM | Buy | Humana Inc | $5,396,000 | +9.2% | 30,000 | +11.1% | 0.96% | -2.3% |
| LBIO | Buy | Lion Biotechnologies Inc | $5,265,000 | +72.7% | 650,000 | +8.3% | 0.94% | +54.5% |
| ARIA | Buy | Ariad Pharmaceuticals Inc | $4,619,000 | +20.5% | 625,000 | +4.2% | 0.82% | +7.8% |
| OMCL | Buy | Omnicell Inc | $4,400,000 | +43.5% | 128,537 | +16.9% | 0.78% | +28.2% |
| XNCR | Buy | Xencor Inc | $4,273,000 | +59.2% | 225,000 | +12.5% | 0.76% | +42.4% |
| VRX | Buy | Valeant Pharm Intl Inc | $4,229,000 | +221.6% | 210,000 | +320.0% | 0.75% | +187.7% |
| NVRO | Buy | Nevro Corp | $4,005,000 | +256.0% | 54,300 | +171.5% | 0.71% | +218.8% |
| MGNX | Buy | Macrogenics Inc | $3,779,000 | +68.0% | 140,000 | +16.7% | 0.67% | +50.1% |
| KITE | New | Kite Pharma Inc | $3,500,000 | – | 70,000 | +100.0% | 0.62% | – |
| ABT | New | Abbott Laboratories | $3,306,000 | – | 84,100 | +100.0% | 0.59% | – |
| NXTM | New | NxStage Medical Inc | $3,150,000 | – | 145,300 | +100.0% | 0.56% | – |
| RVNC | Buy | Revance Therapeutics Inc | $2,992,000 | +0.8% | 220,000 | +29.4% | 0.53% | -9.8% |
| New | NeuroDerm Ltd | $2,349,000 | – | 144,546 | +100.0% | 0.42% | – | |
| CHRS | New | Coherus BioSciences Inc | $2,219,000 | – | 131,357 | +100.0% | 0.39% | – |
| CMRX | Buy | Chimerix Inc | $2,162,000 | -15.4% | 550,000 | +10.0% | 0.38% | -24.3% |
| ADMS | New | Adamas Pharmaceuticals Inc | $1,968,000 | – | 130,000 | +100.0% | 0.35% | – |
| RGLS | Buy | Regulus Therapeutic Inc | $1,012,000 | -27.0% | 350,000 | +75.0% | 0.18% | -34.5% |
| QHCCQ | New | Quorum Health Corp | $602,000 | – | 56,250 | +100.0% | 0.11% | – |
| ADVM | New | Adverum Biotechnologies Inc | $487,000 | – | 154,006 | +100.0% | 0.09% | – |
| CNCE | New | Concert Pharm Inc | $338,000 | – | 30,099 | +100.0% | 0.06% | – |
| GKOS | New | Glaukos Corp | $149,000 | – | 5,100 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-01
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.